JP2016513124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513124A5 JP2016513124A5 JP2015558976A JP2015558976A JP2016513124A5 JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5 JP 2015558976 A JP2015558976 A JP 2015558976A JP 2015558976 A JP2015558976 A JP 2015558976A JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- pharmaceutical composition
- pharmaceutically acceptable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767531P | 2013-02-21 | 2013-02-21 | |
| US61/767,531 | 2013-02-21 | ||
| PCT/US2014/017534 WO2014130752A2 (en) | 2013-02-21 | 2014-02-21 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513124A JP2016513124A (ja) | 2016-05-12 |
| JP2016513124A5 true JP2016513124A5 (https=) | 2017-03-16 |
| JP6277210B2 JP6277210B2 (ja) | 2018-02-07 |
Family
ID=50272738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558976A Expired - Fee Related JP6277210B2 (ja) | 2013-02-21 | 2014-02-21 | 二環式化合物 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9115054B2 (https=) |
| EP (1) | EP2958888B1 (https=) |
| JP (1) | JP6277210B2 (https=) |
| KR (1) | KR102242265B1 (https=) |
| CN (1) | CN105026362B (https=) |
| AR (1) | AR094851A1 (https=) |
| AU (1) | AU2014218883B2 (https=) |
| BR (1) | BR112015019919A2 (https=) |
| CA (1) | CA2902168C (https=) |
| CL (1) | CL2015002358A1 (https=) |
| CY (1) | CY1118641T1 (https=) |
| DK (1) | DK2958888T3 (https=) |
| EA (1) | EA025294B1 (https=) |
| ES (1) | ES2613262T3 (https=) |
| HR (1) | HRP20170247T1 (https=) |
| HU (1) | HUE031626T2 (https=) |
| IL (1) | IL240613B (https=) |
| LT (1) | LT2958888T (https=) |
| MA (1) | MA38425B1 (https=) |
| MX (1) | MX2015010347A (https=) |
| MY (1) | MY173990A (https=) |
| PE (1) | PE20151746A1 (https=) |
| PH (1) | PH12015501793A1 (https=) |
| PL (1) | PL2958888T3 (https=) |
| PT (1) | PT2958888T (https=) |
| RS (1) | RS55703B1 (https=) |
| SG (1) | SG11201506408TA (https=) |
| SI (1) | SI2958888T1 (https=) |
| SM (2) | SMT201700115T1 (https=) |
| TN (1) | TN2015000356A1 (https=) |
| TW (1) | TWI613182B (https=) |
| UY (1) | UY35338A (https=) |
| WO (1) | WO2014130752A2 (https=) |
| ZA (1) | ZA201506965B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3022176B8 (en) | 2013-07-15 | 2019-12-25 | The Regents of the University of California | Azacyclic constrained analogs of fty720 |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| CA2999177A1 (en) | 2015-09-24 | 2017-03-30 | The Regents Of The University Of California | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment |
| KR102482825B1 (ko) | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| WO2021062168A1 (en) * | 2019-09-25 | 2021-04-01 | The Regents Of The University Of California | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| JP4430941B2 (ja) | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬 |
| JP2005531506A (ja) | 2002-03-01 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| EP1697333A4 (en) | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| US7754703B2 (en) | 2005-02-14 | 2010-07-13 | University Of Virginia Patent Foundation | Cycloalkane-containing sphingosine 1-phosphate agonists |
| JP2008530197A (ja) | 2005-02-18 | 2008-08-07 | イノディア インク． | ４−ヒドロキシイソロイシンの類似体及びその使用 |
| CA2600886A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
| WO2006115188A1 (ja) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | ヘテロ環化合物 |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| BRPI0706365A2 (pt) | 2006-01-06 | 2011-03-22 | Sepracor Inc | Cicloalquilaminas como inibidores da recaptação de monoamina |
| JP2009528274A (ja) | 2006-01-27 | 2009-08-06 | ユニバーシティ オブ バージニア パテント ファンデーション | 神経因性疼痛の治療法 |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| US7989472B2 (en) | 2006-03-23 | 2011-08-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| PL2069335T3 (pl) | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| BRPI0720478A2 (pt) * | 2006-12-21 | 2014-01-14 | Abbott Laboratoires | Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato |
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| CN101600700B (zh) | 2007-02-02 | 2013-08-21 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体用于cns病症的新的2-氨基噁唑啉 |
| BRPI0808789A2 (pt) | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
| MX2010003612A (es) | 2007-10-04 | 2010-04-30 | Merck Serono Sa | Derivados de oxadiazol. |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009124022A1 (en) | 2008-04-01 | 2009-10-08 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| US8741923B2 (en) | 2008-12-18 | 2014-06-03 | Merck Serono Sa | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| JP2012517445A (ja) | 2009-02-10 | 2012-08-02 | アボット・ラボラトリーズ | Ｓ１ｐ受容体アゴニストおよびアンタゴニストを調製するための方法 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| US9216972B2 (en) | 2009-10-29 | 2015-12-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| ES2548683T3 (es) | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN102260178A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| US8822510B2 (en) | 2010-07-20 | 2014-09-02 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-Oxadiazole compounds |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| EP2635573B1 (en) | 2010-11-03 | 2014-10-01 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| WO2012129073A2 (en) * | 2011-03-18 | 2012-09-27 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| EP2541155B1 (en) | 2011-04-26 | 2016-02-24 | Panasonic Intellectual Property Management Co., Ltd. | Heating system, and heating system control method |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| JP6324380B2 (ja) | 2012-07-27 | 2018-05-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物 |
-
2014
- 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
- 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
- 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
- 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
- 2014-02-21 SM SM20170115T patent/SMT201700115T1/it unknown
- 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
- 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja not_active Expired - Fee Related
- 2014-02-21 HR HRP20170247TT patent/HRP20170247T1/hr unknown
- 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
- 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
- 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
- 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
- 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
- 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
- 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
- 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
- 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
- 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
- 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
- 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko not_active Expired - Fee Related
- 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
- 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
- 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en not_active Ceased
- 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
- 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
- 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
- 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh not_active Expired - Fee Related
- 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
-
2015
- 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
- 2015-08-14 PH PH12015501793A patent/PH12015501793A1/en unknown
- 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
- 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
- 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
- 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
-
2016
- 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
-
2017
- 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
- 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513124A5 (https=) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| MX381180B (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2016528301A5 (https=) | ||
| JP2016539134A5 (https=) | ||
| AR101177A1 (es) | Inhibidores de la syk | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| JP2010174019A5 (https=) | ||
| EA201390821A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты и их применение | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| JP2017514910A5 (https=) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2016510326A5 (https=) | ||
| IL292465B2 (en) | Neuroactive compounds and methods of use thereof | |
| RU2019121667A (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| JP2013518036A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| RU2017106172A (ru) | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) | |
| JP2014513065A5 (https=) | ||
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112012022632A2 (pt) | Medicamento compreendendo agonista de ep4 | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| EA201990668A1 (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение |